Polycystic ovary syndrome
Conditions
Interventions
Control group:Metformin Hydrochloride Tablets (Beijing Jingfeng Pharmaceutical Group, National Pharmaceutical Approval No. H10983056) taken orally. Usage: 0.5g, taken with a meal, bid. Simultaneously
Carbohydrates account for 50% to 60% of daily total energy, fats account for 25% to 30% of daily total energy, and proteins account for 20% to 30% of daily total energy
Supervise patients' dietary control through WeChat by a dedicated person to avoid eating before bedtime Exercise control: Aerobic exercise 3 times a week for 30 minutes each time, with unlimited forms
And a dedicated person will supervise the patient s weekly exercise status through WeChat. The treatment lasted for 3 months.
Observe group:Metformin Hydrochloride Tablets (Beijing Jingfeng Pharmaceutical Group, National Pharmaceutical Approval No. H10983056) taken orally. Usage: 0.5g, taken with a meal, bid. Simultaneously
And a dedicated person will supervise the patient s weekly exercise status through WeChat. On the basis of the above, acupoint catgut embedding treatment was performed once every 15 days, a total of 6
Sponsors
Jiangwan Hospital in Hongkou District, Shanghai
Eligibility
Sex/Gender
Female
Age
14 Years to 49 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for obesity type PCOS and insulin resistance in Hefei; (2) Traditional Chinese medicine syndrome differentiation belongs to the spleen deficiency phlegm dampness type; (3) Age = 14 years old and = 49 years old; (4) Agree to participate in this study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who also suffer from other serious cardiovascular, cerebrovascular, liver, kidney, and hematopoietic system diseases; (2) Previously or currently diagnosed with psychiatric disorders such as schizophrenia and severe depression; (3) Taking other medications that affect this treatment within the past month; (4) There are contraindications to acupuncture and moxibustion, such as scar constitution, skin sensory disorders, etc; (5) Those who have fertility requirements within 3 months of treatment; (6) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WEIGHT;body mass index;waist to hip ratio;Fasting blood glucose;Fasting insulin;Insulin sensitivity index; | — |
Secondary
| Measure | Time frame |
|---|---|
| effectiveness;Menstrual cycle and follicular development;testosterone;estrogen;Luteinizing hormone;follicle stimulating hormone;Traditional Chinese Medicine Syndrome Points; | — |
Countries
CHINA
Contacts
Public ContactHU XIAOYING
Jiangwan Hospital in Hongkou District, Shanghai
Outcome results
None listed